Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 18/20 | 0.47 |
| ▸ | CCR4 | P51679 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597636 | 1.00 | CCR5 (0.47) | CCR5CCR4KCNH2ALDH1A1MEN1 | |
| SCHEMBL5572571 | 0.92 | CCR5 (0.43) | CCR5CCR4KCNH2MEN1KMT2A | |
| SCHEMBL5572567 | 0.92 | CCR5 (0.43) | CCR5CCR4KCNH2MEN1KMT2A | |
| SCHEMBL4611172 | 0.92 | CCR5 (0.43) | CCR5CCR4KCNH2ALDH1A1L3MBTL1 | |
| SCHEMBL4611178 | 0.92 | CCR5 (0.43) | CCR5CCR4KCNH2ALDH1A1L3MBTL1 | |
| SCHEMBL5576026 | 0.87 | CCR5 (0.62) | CCR5CCR4KCNH2 | |
| SCHEMBL5576018 | 0.87 | CCR5 (0.62) | CCR5CCR4KCNH2 | |
| SCHEMBL5576306 | 0.85 | CCR5 (0.59) | CCR5CCR4KCNH2 | |
| SCHEMBL5576320 | 0.85 | CCR5 (0.59) | CCR5CCR4KCNH2 | |
| SCHEMBL5576318 | 0.85 | CCR5 (0.40) | CCR5CCR4KCNH2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | CCR5 1/4885CCR4 2/4885KCNH2 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.